Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels.

Abstract

In holoendemic Plasmodium falciparum transmission areas such as western Kenya, severe malarial anemia [SMA,hemoglobin (Hb) < 6.0 g/dL, with any density parasitemia] is the most common clinical manifestation of severe malariaresulting in high rates of pediatric morbidity and mortality in these regions. Previous studies associated interleukin (IL)-13with pathogenesis of different infectious diseases, including P. falciparum malaria. However, the functional roles ofpolymorphic variants w ithin the IL -13 promoter in conditioning susceptibility to SMA remain largely unexplored. As such, the association between the IL-13 variants -7402 T/G (rs7719175) and -4729G/A (rs3091307) and susceptibility to SMA was determined in children (n = 387) presenting with clinical symptoms of falciparum malaria and resident in a holoendemic transmission region in western Kenya. Our results indicated no difference in the proportions of individual genotypes among children presenting with non-SMA (n = 222) versus SMA (n = 165). Similarly, there was no associations between the individual genotypes (−7402 T/G and -4729G/A) and SMA. Additional analyses, however, revealed that proportions of individuals with -7402 T/-4729A (TA) haplotype was significantly higher in children presenting with SMA than non-SMA group (P = 0.043). A further multivariate logistic regression analyses, controlling for confounding factors, demonstrated that carriage of the TA haplotype was associated with increased susceptibility to SMA (OR; 1.564, 95% CI; 1.023-2.389,P = 0.039). In addition, circulating levels of IL-13 were comparable between the clinical groups as well as across genotypes and haplotypes. Collectively, findings presented here suggest that haplotypes within the IL-13 promoter at -7402 T/Gand -4729G/A may modulate SMA pathogenesis, but do not affect circulating IL-13 levels.

Keywords: IL-13, Promoter polymorphisms, Haplotypes, Severe malaria anemia
Overall Rating

0

5 Star
(0)
4 Star
(0)
3 Star
(0)
2 Star
(0)
1 Star
(0)
APA

A, O (2024). Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels.. Afribary. Retrieved from https://tracking.afribary.com/works/interleukin-il-13-promoter-polymorphisms-7402-t-g-and-4729g-a-condition-susceptibility-to-pediatric-severe-malarial-anemia-but-not-circulating-il-13-levels

MLA 8th

A, Okeyo "Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels." Afribary. Afribary, 04 Jun. 2024, https://tracking.afribary.com/works/interleukin-il-13-promoter-polymorphisms-7402-t-g-and-4729g-a-condition-susceptibility-to-pediatric-severe-malarial-anemia-but-not-circulating-il-13-levels. Accessed 22 Dec. 2024.

MLA7

A, Okeyo . "Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels.". Afribary, Afribary, 04 Jun. 2024. Web. 22 Dec. 2024. < https://tracking.afribary.com/works/interleukin-il-13-promoter-polymorphisms-7402-t-g-and-4729g-a-condition-susceptibility-to-pediatric-severe-malarial-anemia-but-not-circulating-il-13-levels >.

Chicago

A, Okeyo . "Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels." Afribary (2024). Accessed December 22, 2024. https://tracking.afribary.com/works/interleukin-il-13-promoter-polymorphisms-7402-t-g-and-4729g-a-condition-susceptibility-to-pediatric-severe-malarial-anemia-but-not-circulating-il-13-levels